Nuclera, a biotechnology company, has entered a collaboration with Cytiva, a global life sciences leader, to accelerate the production, purification and characterization of proteins required for drug research and development. The partnership will leverage both Nuclera’s eProtein Discovery System and Cytiva’s Biacore surface plasmon resonance (SPR) technology. Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact w...